{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[14,2,14,3],[15,2,15,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910337937903321"]
[null,null,"Titolo",null,"Antidepressants : From Biogenic Amines to New Mechanisms of Action / / edited by Matthew Macaluso, Sheldon H. Preskorn"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019"]
[null,null,"ISBN",null,"9783030109493"]
[{"$nulls":4},"3030109496"]
[null,null,"Edizione",null,"[1st ed. 2019.]"]
[null,null,"Descrizione fisica",null,"1 online resource (xii, 442 pages) : illustrations (some color), charts"]
[null,null,"Collana",null,"Handbook of Experimental Pharmacology, , 1865-0325 ; ; 250"]
[null,null,"Disciplina",null,"615"]
[{"$nulls":4},"615.78"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Psychiatry"]
[{"$nulls":4},"Neurosciences"]
[{"$nulls":4},"Neuroscience"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Part 1: Overview and General Principles -- 1. Impact, Diagnosis, Phenomenology, and Biology -- Part 2: The Past – from antiquity to 1970 including TCAs and MAOIs -- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look? -- Part 3: The Present- 1970 to 2016 -- 3. Clinical Implications of the STAR*D Trial -- 4. Pharmacogenomics and Biomarkers of Depression -- 5. Therapeutic Drug Monitoring of Antidepressants -- 6. Selective Serotonin Reuptake Inhibitors -- 7. Serotonin and Norepinephrine Reuptake Inhibitors -- 8. Neurostimulation Therapies -- 9. Current Role of Herbal and Natural Preparations -- Part 4: The future -- 10. Role of Inflammation in Depression and Treatment Implications -- 11. NMDA Antagonists for Treatment-Resistant Depression -- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development -- 13. Other Antidepressants -- Part 5: Use of Antidepressants in Special Populations -- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders -- 15. Treatment of Depression in Women -- 16. Management of Late-Life Depression -- 17. The Use of Antidepressants in Bipolar Depression."]
[null,null,null,"Sommario/riassunto","This volume reviews the known neurobiology of depression and "]
[{"$nulls":4},"combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs."]